ReNeuron’s full year results highlight the progress of its stem cell therapy candidates with data from its CTX stem cell therapy candidate for stroke (Phase II), critical limb ischaemia (Phase I) and hRPC stem cell therapy candidate for retinitis pigmentosa (Phase I/II) due in the next twelve months. Positive data from each would be a share price catalyst and offer significant upside potential. We remain at Buy and look forward to data over the coming year.
07 Jul 2016
N+1 Singer - ReNeuron Group - Full year results: Phase II stroke data due in Q4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - Full year results: Phase II stroke data due in Q4
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
07 Jul 2016 -
Author:
Sheena Berry -
Pages:
3
ReNeuron’s full year results highlight the progress of its stem cell therapy candidates with data from its CTX stem cell therapy candidate for stroke (Phase II), critical limb ischaemia (Phase I) and hRPC stem cell therapy candidate for retinitis pigmentosa (Phase I/II) due in the next twelve months. Positive data from each would be a share price catalyst and offer significant upside potential. We remain at Buy and look forward to data over the coming year.